Use of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The size of the dedifferentiated component in liposarcoma, not overall tumor size, predicts patient outcomes. Larger dedifferentiated areas and higher mitotic counts correlate with adverse events in MDM2-amplified liposarcomas.
Area Of Science
- Oncology
- Molecular Pathology
- Surgical Pathology
Background
- Atypical lipomatous tumor/well-differentiated liposarcoma can progress to dedifferentiated liposarcoma, impacting patient prognosis.
- Amplification of chromosome 12q13-15, including the MDM2 proto-oncogene, is a hallmark molecular signature for these liposarcomas.
Purpose Of The Study
- To evaluate the correlation between clinicopathologic features and outcomes in MDM2-amplified liposarcomas.
- To determine if the extent of the dedifferentiated component influences patient prognosis.
Main Methods
- Retrospective review of pathology reports and clinical records for 123 surgically resected MDM2-amplified liposarcomas.
- Univariate and multivariate logistic regression analyses to identify predictors of adverse events (metastasis/death).
- Log-rank tests to compare survival trends.
Main Results
- The largest single dimension of the dedifferentiated component and higher mitotic count were significantly associated with adverse events in multivariate analysis.
- Univariate analysis also identified the percentage of cells with chromosome 12 gain and modified FNCLCC grade 3 as associated with adverse events.
- No significant association was found between local recurrence, overall tumor size/volume, MDM2 copy number, or MDM2/chromosome 12 centromere probe ratio and adverse outcomes.
Conclusions
- Staging dedifferentiated liposarcoma based on the size of its dedifferentiated component is a more effective predictor of patient outcome.
- The size of the dedifferentiated component is a crucial factor in assessing the prognosis of MDM2-amplified liposarcomas.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
